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ABSTRACT
The population of elderly individuals has increased
significantly over the past century and is predicted
to rise even more rapidly in the future. Ageing is
a major risk factor for many diseases such as
neurodegenerative disease, diabetes and cancer.
This highlights the importance of understanding the
mechanisms involved in the ageing process. One
plausible mechanism for ageing is accumulation
of mutations in the mitochondrial genome. In this
review, we discuss some of the most convincing
data surrounding age-related mtDNA mutations and
the evidence that these mutations contribute to
the ageing process.
INTRODUCTION
Throughout the lifetime of an organism, the production
of energy is a fundamental requirement. The majority of
this energy, in the form of ATP, is produced through
the process of oxidative phosphorylation (OXPHOS); the
complexes involved are situated in the inner mitochondrial
membrane. Mitochondria are intracellular organelles that
contain their own DNA (mtDNA), which is distinct from
nuclear DNA and can be replicated independently of the
cell cycle. This allows the production of more mtDNA
molecules capable of producing proteins for OXPHOS
under high-energy demands. There is a small, 1kb non-
coding control region on the mitochondrial genome,
but apart from this, the rest of the 16.5kb genome is
entirely transcribed. The mitochondrial genome codes
for 37 genes, which includes 13 essential polypeptides of
the OXPHOS system, 22 tRNAs and 2 rRNAs which are
required for intramitochondrial protein synthesis. The
vast majority of the proteins involved in OXPHOS are
encoded by nuclear DNA, translated in the cytoplasm and
imported into the mitochondria.
MtDNA is present in multiple copies within each cell;
the actual number varies between cell type and on the
energy demands within each tissue. The multi-copy nature
of mtDNA means that any mutations occurring on the
mitochondrial genome can exist amongst wild-type copies
in a situation referred to as heteroplasmy (1). These
mutant copies do not exert a biochemical phenotype on
a cell until the mutant copies reach a certain level. This
threshold of mutant: wild type can vary depending on the
speciﬁc mutation and on cell type. The types of mtDNA
mutations which can occur vary from single point
mutations to large-scale rearrangements such as deletions
and duplications (1). Mutations on the mitochondrial
genome are thought to arise due to the close proximity of
mtDNA to the OXPHOS system located on the inner
mitochondrial membrane, making the mitochondrial
genomes vulnerable to damage through the leakage of
reactive oxygen species (ROS) during the OXPHOS
process. Mitochondria are able to counteract the produc-
tion of ROS with antioxidant defence systems which can
detoxify the amount of ROS produced, however some
ROS do evade these processes and are able to damage
mtDNA as well as proteins and lipids. MtDNA molecules
are contained within nucleoids, which contain essential
maintenance proteins including the mitochondrial trans-
cription factor A gene (TFAM) which eﬀectively coats the
mtDNA molecule. However, it is uncertain whether
this oﬀers any protection against ROS, and this along
with limited repair capacity means that there is a high
mutation rate. This increased susceptibility of mtDNA to
ROS leading to mutations has led to the proposal of the
mitochondrial theory of ageing (2,3). This theory suggests
that damaged mitochondrial genomes lead to ineﬃcient
OXPHOS causing the production of more ROS which
will further damage the mtDNA, resulting in a so-called
‘vicious cycle’.
Evidence foraccumulation of mtDNA mutations withage
In support of a role for mtDNA mutations in ageing,
both mtDNA point mutations and deletions have been
described to accumulate on the mitochondrial genome
with age in a variety of tissues (4–8). High levels of
a m.414T>G transversion was found in ﬁbroblasts from
half of subjects older than 65 years but was absent from
all younger individuals (6). The m.414T>G mutation has
most recently been shown to occur signiﬁcantly more
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exposed skin sites suggesting that increased oxidative
stress through ultraviolet (UV) radiation exposure results
in the production of this mutation (9). The absence or
marginal presence of the m.414T>G mutation in skeletal
muscle, brain, heart, lymph nodes and spleen has led to
the suggestion that it may be tissue speciﬁc (10–12).
Suggestions of tissue-speciﬁc ‘hot-spots’ for point muta-
tions on the mitochondrial genome have also been
described (13), with the clonal expansion of point
mutations accumulating with age in cardiomyocytes and
buccal epithelium, but the distribution of these point
mutations were described to be signiﬁcantly diﬀerent.
The region 407–411 of mtDNA which is close to the age-
associated m.414T>G mutation has also been suggested
as being a hot-spot for mutations in muscle mtDNA (12).
Work in our own laboratory on colonic epithelium has
shown an age-dependent increase of clonally expanded
point mutations, with 50% of colonocytes taken from
aged patients harbouring a point mutation (7). However
we have not observed any evidence for speciﬁc mutation
‘hot-spots’, with the distribution of the point mutations
spread throughout the genome (7).
The age-related accumulation of mtDNA deletions has
also been described. The initial observations were focused
on a well-characterized 4977bp deletion, the so-called
‘common deletion’. This deletion had previously been
identiﬁed in a number of patients with mitochondrial
disease (Kearns Sayre syndrome and chronic progressive
external ophthalmoplegia). Studies on tissues from normal
subjects showed that the common deletion was detectable
in heart muscle, skeletal muscle, brain and other tissues
of older human subjects, but not from the same tissues
from young individuals (14–16). Technical diﬃculties in
the study of mtDNA deletions resulted in the majority
of early studies focussing on identifying single deletions
in ageing tissues, such as the common deletion and the
levels detected even in tissues from very elderly individuals
rarely exceeded 1%. Thus, it was thought that these very
low levels of mtDNA deletions associated with ageing
were unlikely to contribute to the ageing process. However
it was shown that if mtDNA mutations accumulate to
high levels focally in a small subset of cells, then this leads
to cells which have respiratory chain deﬁciency, detected
by an absence of staining for cytochrome c oxidase (COX)
activity (17,18).
Respiratory deﬁcient cells have since been shown
to accumulate with age in a number of tissues (4,7,19)
(Figure 1). Also, it was apparent that the common dele-
tion was only one of several diﬀerent possible deletions
present in ageing human tissues and the development of
single-cell-based PCR techniques allowed the measure-
ment of all deletions in single cells. Recently, we and
colleagues were the ﬁrst to report the age-related accumu-
lation of mtDNA deletions to very high levels (50%)
in substantia nigra neurons from both normal controls
and individuals with Parkinson’s disease (4,5). Analysis of
mtDNA deletions using long-range PCR in individual
neurons showed that each neuron harboured a diﬀerent
mtDNA deletion usually consisting of just one type, which
suggests that these mtDNA deletions arose through
clonal expansion (see later) (Figure 2). Respiratory
chain-deﬁcient neurons had signiﬁcantly higher level of
mtDNA deletions than neurons with normal COX
activity, supporting the hypothesis that these deletions
were the cause of the respiratory chain deﬁciency. Similar
observations have also been made by analysing ageing
muscle ﬁbres. These studies also showed that in age-
related respiratory chain-deﬁcient ﬁbres there was clonal
expansion of mtDNA deletions, with over 80% of
mtDNA in the aﬀected ﬁbres harbouring a clonally
expanded deletion (20).
Are mtDNA mutationsimportant inhuman ageing?
In humans, the increase in mtDNA mutations with age
does not prove that they have a role in the ageing process;
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Figure 1. Histochemical staining to observe the presence of respiratory
chain-deﬁcient cells (blue) amongst respiratory chain normal cells
(brown) in aged: hippocampus (A), choroid plexus (B) and colonic
epithelium (C).
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damage. It has been reported that mitochondria isolated
from the ﬁbroblasts of old animals that was subsequently
microinjected into young cells can lead to cellular degener-
ation, similar results were also achieved from young,
partially uncoupled mitochondria (21,22). Although the
nature of the mtDNA abnormalities was not investigated
in these studies, these results demonstrate that altered
mitochondria may be playing a crucial role in the decline
in cellular function. However, a recent study has shown
that somatic mutation accumulation with age is dependent
on nuclear genetic background in mice and not associated
with increase in ROS or senescence (23). This suggests that
the accumulation of the mtDNA mutations may not be as
straightforward as ﬁrst thought and that an individual’s
nuclear background may aﬀect their susceptibility to the
accumulation of mtDNA mutations and the resulting
phenotype. This could have some eﬀect on the interpreta-
tion of studies involving mtDNA mutations in cybrids,
where there has been some evidence for increased ROS
production with certain mtDNA mutations as these
diﬀerences may vary in other nuclear backgrounds (24,25).
In the skin, changes associated with normal ageing such
as wrinkles, changes in pigmentation and the increased
incidence of skin cancer are accelerated by exposure to the
potent mutagen UV radiation. MtDNA deletions occur
more frequently in sun-exposed areas that have been
subjected to photoageing (26–29). These observations
support the theory that increased oxidative stress results
in mtDNA damage and the production of mutations.
It is unknown at present what eﬀects these mtDNA
deletions have on the normal functioning of the skin.
An important observation supporting a role of mtDNA
mutations in age-related cellular degeneration has been
shown by the age-associated loss of muscle mass, termed
sarcopenia, which is a common feature in aged human
subjects (30). Atrophy in skeletal muscle ﬁbres from
rhesus monkeys was shown to correlate in those sections
with respiratory chain abnormalities and mtDNA dele-
tions, compared to those sections without respiratory
chain abnormalities (31), suggesting that mitochondrial
dysfunction may be a contributing factor to sarcopenia.
To strengthen this ﬁnding, in sarcopenic rats, mtDNA
deletions have been shown to co-localize with respiratory
chain abnormalities, atrophy and splitting (32,33). These
observations provide a strong association that mtDNA
deletions contribute to the age-related decline of muscle
mass and function.
The age-associated accumulation of high levels of
mtDNA deletions in the dopamine producing, pigmented
neurons of the substantia nigra is additional support for
a role of mtDNA mutations in the ageing process.
This region of the brain loses neurons at a rate of 5%
per decade (34) and there is an even greater neuronal loss
in patients with Parkinson’s disease. It is unknown at
present whether the age-related loss of neurons in the
substantia nigra is due to the accumulation of mtDNA
deletions in these neurons. However, mtDNA dysfunction
resulting from reduced mtDNA expression has been
shown to cause a parkinsonian phenotype in mice (35).
The cause of the reduced mtDNA expression in these mice
is due to selective knockout of TFAM in dopamine
producing neurons within the substantia nigra. The mice
had respiratory chain deﬁciency accompanied by cell loss,
selectively in this region and provides support that normal
mtDNA expression is crucial for the functioning and
viability of neurons within the substantia nigra. Recent
studies have also shown that substantia nigra neurons
have an unusual reliance on certain calcium channels to
maintain their pacemaker currents and this seems likely
to make them particularly sensitive to mitochondrial
dysfunction (36).
Ageingmouse model
A major advance in the support for a direct role of
mtDNA mutations in the ageing process was demon-
strated by two groups who created mice with a premature
ageing phenotype due to knock-in mutations in the
exonuclease domain of polymerase gamma (POLG)
(37,38). POLG is the only known polymerase to be
targeted to mitochondria and as such is thought to be
solely responsible for the maintenance of all aspects of
mtDNA including replication and repair. In humans,
POLG is a heterotrimeric enzyme consisting of a catalytic
subunit (POLGA) and two identical accessory subunits
(POLGB) (39). Therefore it was no surprise that a
mutation in the exonuclease domain (proofreading) of
POLGA resulted in the mice having increased mtDNA
mutation rates as detected by cloning analysis (38). Some
controversy exists over the validity of the mutation rates
detected by the cloning methodology and a recent paper
has re-analysed the mutation rates in the POLG mice
using a random capture methodology (RMC) suggesting
the mutation rates calculated by the cloning method are
too high (40). However, even using the RMC method,
the mutation rates of the POLG mice are higher than their
wild-type counterparts.
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Figure 2. Long-range PCR of substantia nigra neurons showing the
presence of mtDNA deletions in 10 pooled neurons (lanes 1 and 2),
ﬁve pooled neurons (lanes 3 and 4), a single neuron (lanes 5 and 6) and
control DNA (lane 7). The ladder on the left of the gel is a 1kb ladder.
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there is no evidence of increased ROS production (41),
which is predicted by the mitochondrial theory of ageing.
In addition, mRNA levels of antioxidant defence systems
were unaﬀected, suggesting a lack of a ROS-induced stress
response. The authors question the role of ROS in the
premature ageing symptoms displayed by these mice and
suggest that the respiratory chain deﬁciency may be the
major factor involved in the age-associated decline in
function, presumably caused through the generation of
increased mtDNA mutations. An alternative explanation
is that the generation of mtDNA mutations through
ineﬃcient POLG may be downstream from mechanisms
that generate ROS (42). Therefore, it is possible that ROS
can induce mtDNA mutations directly or through
damaging POLG to make it error-prone, but the resulting
mtDNA mutations do not increase the production of
ROS. To further confuse the role of ROS in ageing is
the observation that high oxidative damage levels are
observed in the longest-living rodent, the naked mole rat
(43). It has also been reported that heterozygous SOD2
knockouts have increased oxidative damage but normal
lifespan (44). All these results seem to contradict the
simplest assumption that increased ROS production
promotes accelerated ageing. However, these results may
be an indication that as discussed previously, other factors
such as the nuclear genetic background play a crucial role
in the susceptibility to the eﬀects of increased oxidative
damage.
Clonal expansion ofmtDNA mutations
Whilst there remains some controversy over the best
method to measure mutation rates, in terms of respiratory
chain deﬁciency (and possibly ageing) the crucial factor
in determining dysfunction is the clonal expansion of
the mtDNA mutation within a cell. Clonal expansion of
a speciﬁc mtDNA mutation has been described by many
diﬀerent authors in both disease and ageing tissues
(4,5,7,13,20,45). In patients with primary mtDNA defects,
the clonally expanded mutation is identical between
diﬀerent cells, whereas in ageing diﬀerent mutations are
seen in adjacent cells. In ageing it seems likely that the
mutation was derived from a single event and this
mutation subsequently expands to become the predomi-
nant species within an individual cell. The precise
mechanism of clonal expansion is unknown, but several
authors have proposed a random genetic drift model (46).
An important research focus should be to understand the
mechanism of clonal expansion in diﬀerent tissues,
especially post-mitotic tissues where the rate of replication
of the mitochondrial genome is uncertain. Unfortunately,
at present, methods to determine rates of mtDNA replica-
tion cannot be diﬀerentiated from those measuring repair.
In post-mitotic tissues, DNA repair is an active process
and may even be involved in the generation of mutations.
Whatdo patients withmitochondrial diseases tell
usabout mitochondrial ageing?
An increasing number of patients are being described with
primaryor secondary defectsof themitochondrial genome.
Secondary defects are those due to mutations in nuclear
genes involved in mtDNA maintenance. These patients
present with a variety of diﬀerent clinical features,
particularly involving tissues heavily dependent upon
OXPHOS. These patients have been crucial in our
understanding of human mitochondrial genetics, but
also provide important clues as to the potential role of
mtDNA in the ageing process. These include:
(i) The concept of threshold for an individual mtDNA
mutation leading to respiratory chain deﬁciency in
an individual cell. This phenomenon is crucial to
understanding the importance of clonal expansion
in ageing tissues. Indeed an important part of the
diagnosis of mtDNA mutations is that these
mutations have to show a threshold to conﬁrm the
pathogenic nature of any speciﬁc point mutation.
This conﬁrms again the importance of clonal
expansion of somatic mutations before a biochem-
ical defect is seen.
(ii) MtDNA mutations lead to human pathology.
In patients with mtDNA mutations, there is both
clinical disease and evidence of cell loss and
dysfunction. These changes are much more
marked than those seen with ageing but are still
relevant since we believe the respiratory chain-
deﬁcient cells are essentially the same in both
mtDNA disease and ageing.
The clinical features of patients with mtDNA disease
are very diﬀerent from ageing although this is not
surprising since these patients are born with high levels
of a single mtDNA mutation. The phenotype will depend
upon both the nature of the mtDNA mutation and the
level in a number of diﬀerent tissues. More relevant to
ageing are those patients with primary nuclear mutations
involved in mtDNA maintenance. These patients acquire
mtDNA mutations throughout life, often mtDNA dele-
tions. This is clearly similar to the observations in
post-mitotic tissues in ageing individuals. The level of
mtDNA mutations is much greater in tissues than seen in
ageing since there is often severe disease leading to
disability or death. Genetic defects of POLG are the
most important of the defects leading to secondary
mtDNA defects (47). Interestingly one of the phenotypes
seen in these patients is Parkinsonism associated with loss
of cells in the substantia nigra and high levels of deleted
mtDNA (48–50). This is remarkably similar to recent
observations in elderly tissues and conﬁrms that defects of
mtDNA can lead to cell loss in this region of the brain.
Whilst patients with either primary or secondary defects
of mtDNA do not present good phenotypic models of
human ageing, they do show that these genetic defects
of the mitochondrial genome can lead to pathology and
thus are supportive of a role of mtDNA mutations in
human ageing.
Cell death
The ultimate insult that mtDNA mutations could have
on a cell would be to impair the function so much as to
lead to cell death. It is well known that mitochondria are
7402 Nucleic Acids Research, 2007, Vol. 35, No. 22central players in apoptosis, or programmed cell death.
Therefore, if high levels of mtDNA mutations lead to
mitochondrial dysfunction, it seems possible that this will
compromise the cell and result in apoptosis. Respiratory
chain deﬁciency, caused by reduced mtDNA expression,
has been shown to be associated with increased apoptosis
in TFAM knockout animal models (51). Mitochondrial
dysfunction, induced by a variety of oxidative stresses has
been shown to induce apoptosis in cultured neurons and
cardiomyocytes (52–54), but evidence of underlying
mtDNA mutations as the cause was not investigated in
these studies. However, cleaved caspase-3 an indicator of
apoptosis, was increased in a variety of tissues in the
POLG mice (37), suggesting that the increased mtDNA
mutation load in these animals could be responsible for
the decline in tissue function with age. It has also been
recently reported that genes involved in apoptosis are
upregulated in the cochlear of the POLG-mutated mice
and therefore the resulting eﬀect could be the age-related
hearing loss in these mice (55). In addition increased
TUNEL staining was observed in the hippocampus in
mitochondrial late-onset neurodegeneration (MILON)
mice (56), which are mice with mtDNA depletion due to
a knockout of TFAM. The TUNEL staining in these
MILON mice was often observed before any obvious
cell loss.
CONCLUSIONS
In this review, we have shown that there is increasing
evidence to suggest that the accumulation of mtDNA
mutations with age could play a role in the decline in
cellular function within many tissues. We have summa-
rized some of this evidence in Figure 3, which shows that
mtDNA mutations could be caused by either replication
errors or increased oxidative stress, if a mutated mtDNA
molecule is then allowed to replicate and clonally expand
within a cell, this cell may become respiratory chain
deﬁcient. This compromised energy production could lead
to the demise of the cell, and if substantial cell loss is
observed this may result in tissue dysfunction and the
onset of ageing. If this is correct then by preventing the
mtDNA mutations from arising should increase lifespan.
Support for this theory has already been shown with
the observation of an increase in lifespan of mice over-
expressing human catalase localized to mitochondria (57).
These mice had reduced cardiac pathology and cataract
development along with reduced oxidative damage
mirrored by a reduction in mtDNA deletions compared
to wild-type mice. Catalase converts H2O2 into water and
oxygen preventing it from becoming a highly reactive
hydroxyl radical. Therefore, the resulting reduced oxida-
tive damage followed by extension of lifespan in these
mice supports the production of mitochondrial ROS as
a factor in the ageing process. There are many challenges
ahead. For example, we lack knowledge of several funda-
mental aspects of mitochondrial genetics such as the
mechanisms causing mtDNA mutations and their sub-
sequent clonal expansion. In addition, there are likely
to be tissue-speciﬁc diﬀerences and inﬂuence on these
processes of nuclear genetic factors.
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